2005
DOI: 10.1373/clinchem.2005.057885
|View full text |Cite
|
Sign up to set email alerts
|

Additive-Aggravated Assays: An Authoritative Answer

Abstract: Immunoassay interferences are diverse in scope (1)(2)(3)(4)(5)(6)(7)(8) and are the subject of several recent large-scale studies (9, 10 ), opinions, and editorials (6,11 ). Most interferences originate from components of the sample (e.g., human anti

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2005
2005
2005
2005

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 18 publications
0
2
0
Order By: Relevance
“…Collection of blood in certain batches of Vacutainer ® SST tubes was associated with errors in some immunoassays on certain immunoassay platforms [e.g., biases of 20% to 30% for total thyroxine (T 4 ), total triiodothyronine (T 3 ), and cortisol and Ϫ15% to 20% for follicle-stimulating hormone (FSH)]. These errors have been attributed to contamination of samples with surfactants that are used to coat the tubes; the surfactant can release reagent antibodies from some solid-phase materials used in immunoassay methods (5,6 ).…”
Section: To the Editormentioning
confidence: 99%
See 1 more Smart Citation
“…Collection of blood in certain batches of Vacutainer ® SST tubes was associated with errors in some immunoassays on certain immunoassay platforms [e.g., biases of 20% to 30% for total thyroxine (T 4 ), total triiodothyronine (T 3 ), and cortisol and Ϫ15% to 20% for follicle-stimulating hormone (FSH)]. These errors have been attributed to contamination of samples with surfactants that are used to coat the tubes; the surfactant can release reagent antibodies from some solid-phase materials used in immunoassay methods (5,6 ).…”
Section: To the Editormentioning
confidence: 99%
“…Among the described mutations and polymorphisms (5,6 ), c.103delG accounts for 37% of mutant alleles, allowing diagnosis of PH2 to be made by genetic testing (5 ). One of the polymorphisms, c.579GϾA, occurs in exon 6, and the G allele has been shown to have a frequency of 0.68 in genomic DNA from PH2 patients (5 ).…”
Section: Tissue Differences In the Expression Of Mutations And Polymomentioning
confidence: 99%